Amylyx (AMLX) news

Amylyx Pharmaceuticals prices upsized $500M offering of stock

Amylyx Pharmaceuticals (Nasdaq: AMLX) has priced an upsized public offering of its common stock, raising $500 million in gross proceeds , according to a press release dated August 19, 2026. The offering includes 142,857,142 shares at a public offering price of $3.50 per share, with an additional…

Mizuho raises target price to $42 from $30 for Amylyx Pharmaceuticals, Inc.

Mizuho Securities has raised its price target for Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) to $42 from $30, while maintaining an Outperform rating. The updated target aligns with the broader analyst consensus of Strong Buy, with price targets ranging from $20 to $55. Amylyx’s stock currently…

Amylyx Pharmaceuticals share offering said to price Wednesday

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) announced the pricing of a public offering of common stock on Wednesday, with the company issuing 17,500,000 shares at $10.00 per share, generating expected gross proceeds of $175.0 million before underwriting discounts and expenses. The offering includes…

Amylyx Pharmaceuticals: proceeds to fund Avexitide pre-commercial activities, R&D, and general corporate purposes

Amylyx Pharmaceuticals shares surge 64%, a record one-day gain

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) shares surged 64% in after-hours trading on August 18, 2026, marking a record one-day gain for the company. The sharp rise followed the announcement that the company would release topline results from its pivotal Phase 3 LUCIDITY clinical trial of…